At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France, discusses the ongoing phase 3 ARAMIS trial, which is evaluating the efficacy and safety of the novel androgen receptor inhibitor, ODM-201, in men with high-risk non-metastatic castration-resistant prostate cancer.
ARAMIS: Phase 3 trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancer
23rd July 2015
Oncology
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now